

NOVO NORDISK A S
Form 6-K
June 02, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

JUNE 2, 2010

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

**Novo Allé
DK- 2880, Bagsvaerd
Denmark**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Company Announcement

31 May 2010

Novo Nordisk A/S – Share repurchase programme

On 27 April 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 27 April 2010 to 3 August 2010.

Since the announcement as of 25 May 2010, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,460,500		673,072,272
25 May 2010	70,000	446.9090	31,283,630
26 May 2010	50,000	456.8903	22,844,515
27 May 2010	75,000	460.4375	34,532,813
28 May 2010	150,000	469.7040	70,455,600
Accumulated under the programme	1,805,500		832,188,830

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 5,000 B shares in the period from 25 May 2010 to 28 May 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 36,550,372 treasury shares, corresponding to 5.9% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Company Announcement no 28 / 2010

Page 1 of 2

Novo Nordisk A/S Novo Allé Telephone: Internet: CVR no:
Investor Relations 2880 Bagsværd +45 4444 8888 novonordisk.com 24256790
Denmark Telefax:

+45 4444 6626

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media: Investors:
Mette Kruse Danielsen Klaus Bülow Davidsen
Tel: (+45) 4442 3883 Tel: (+45) 4442 3176
mkd@novonordisk.com klda@novonordisk.com
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com

In North America: *In North America:*
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hmmm@novonordisk.com

Company Announcement no 28 / 2010

Page 2 of 2

Novo Nordisk A/S Novo Allé Telephone: Internet: CVR no:
Investor Relations 2880 Bagsværd +45 4444 8888 novonordisk.com 24256790
Denmark Telefax:
+45 4444 6626

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: JUNE 2, 2010

NOVO NORDISK A/S

Lars Rebieen Sørensen,

President and Chief Executive Officer
